HK1204553A1 - Extended-release formulation for reducing the frequency of urination and method of use thereof - Google Patents

Extended-release formulation for reducing the frequency of urination and method of use thereof Download PDF

Info

Publication number
HK1204553A1
HK1204553A1 HK15105034.0A HK15105034A HK1204553A1 HK 1204553 A1 HK1204553 A1 HK 1204553A1 HK 15105034 A HK15105034 A HK 15105034A HK 1204553 A1 HK1204553 A1 HK 1204553A1
Authority
HK
Hong Kong
Prior art keywords
analgesic agents
hours
release
pharmaceutical composition
analgesic
Prior art date
Application number
HK15105034.0A
Other languages
English (en)
Chinese (zh)
Inventor
大衛‧
大卫‧A‧迪尔
‧迪爾
伊丽娅‧A‧沃尔夫松
伊麗婭‧
‧沃爾夫松
Original Assignee
韦尔斯利医药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/424,000 external-priority patent/US8236857B2/en
Priority claimed from US13/487,348 external-priority patent/US20120244221A1/en
Application filed by 韦尔斯利医药有限公司 filed Critical 韦尔斯利医药有限公司
Publication of HK1204553A1 publication Critical patent/HK1204553A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15105034.0A 2012-03-19 2013-03-14 Extended-release formulation for reducing the frequency of urination and method of use thereof HK1204553A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/424,000 US8236857B2 (en) 2010-07-08 2012-03-19 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/424,000 2012-03-19
US13/487,348 2012-06-04
US13/487,348 US20120244221A1 (en) 2010-07-08 2012-06-04 Extended-release formulation for reducing the frequency of urination and method of use thereof
PCT/US2013/031617 WO2013142274A1 (en) 2012-03-19 2013-03-14 Extended-release formulation for reducing the frequency of urination and method of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
HK18110965.0A Division HK1251469A1 (zh) 2012-03-19 2015-05-27 用於缓解尿频的延长释放制剂及其使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK18110965.0A Addition HK1251469A1 (zh) 2012-03-19 2015-05-27 用於缓解尿频的延长释放制剂及其使用方法

Publications (1)

Publication Number Publication Date
HK1204553A1 true HK1204553A1 (en) 2015-11-27

Family

ID=49223209

Family Applications (3)

Application Number Title Priority Date Filing Date
HK15105034.0A HK1204553A1 (en) 2012-03-19 2013-03-14 Extended-release formulation for reducing the frequency of urination and method of use thereof
HK18110965.0A HK1251469A1 (zh) 2012-03-19 2015-05-27 用於缓解尿频的延长释放制剂及其使用方法
HK18103371.3A HK1243921A1 (zh) 2012-03-19 2018-03-10 用於缓解尿频的延长释放制剂及其使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK18110965.0A HK1251469A1 (zh) 2012-03-19 2015-05-27 用於缓解尿频的延长释放制剂及其使用方法
HK18103371.3A HK1243921A1 (zh) 2012-03-19 2018-03-10 用於缓解尿频的延长释放制剂及其使用方法

Country Status (15)

Country Link
EP (2) EP2827852A4 (enrdf_load_stackoverflow)
JP (5) JP2015510928A (enrdf_load_stackoverflow)
KR (4) KR20140134333A (enrdf_load_stackoverflow)
CN (4) CN107157991A (enrdf_load_stackoverflow)
AU (4) AU2013235518B2 (enrdf_load_stackoverflow)
BR (2) BR112014020271A8 (enrdf_load_stackoverflow)
CA (2) CA2866853A1 (enrdf_load_stackoverflow)
HK (3) HK1204553A1 (enrdf_load_stackoverflow)
MX (3) MX2014011128A (enrdf_load_stackoverflow)
MY (2) MY174090A (enrdf_load_stackoverflow)
NZ (6) NZ718163A (enrdf_load_stackoverflow)
RU (3) RU2669565C2 (enrdf_load_stackoverflow)
SG (2) SG11201500408VA (enrdf_load_stackoverflow)
WO (2) WO2013142197A1 (enrdf_load_stackoverflow)
ZA (2) ZA201405862B (enrdf_load_stackoverflow)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
JP2016525548A (ja) 2013-07-23 2016-08-25 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉ� Β−３アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物
CN106714805A (zh) * 2014-06-06 2017-05-24 韦尔斯利医药有限公司 降低排尿频率的药物制剂及其使用方法
KR101809908B1 (ko) * 2014-07-21 2018-01-25 주식회사 종근당 5-알파환원효소억제제를 포함하는 조성물
CN106999538A (zh) * 2014-11-20 2017-08-01 阿勒根公司 包含去氨加压素与α‑肾上腺素能受体拮抗剂组合的方法和组合物
WO2017058428A1 (en) * 2015-09-30 2017-04-06 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
AU2016331879A1 (en) * 2015-09-30 2018-05-17 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
CN105238124B (zh) * 2015-11-16 2018-02-09 太仓东能环保设备有限公司 一种抗菌腻子粉
JP6294924B2 (ja) 2016-09-05 2018-03-14 株式会社Ｓｕｂａｒｕ 車両の走行制御装置
JP2019031556A (ja) * 2018-10-31 2019-02-28 ウェルズリー ファーマスーティカルズ、エルエルシー 排尿頻度を減少させるための医薬製剤およびその使用の方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010040819A (ko) * 1998-02-10 2001-05-15 가마꾸라 아끼오 제어방출형 제제
US20020102309A1 (en) * 1999-09-14 2002-08-01 Jane C. I. Hirsh Controlled release formulation for administration of an anti-inflammatory naphthalene derivative
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
WO2003070233A1 (en) * 2002-02-19 2003-08-28 Pharmacia Corporation Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
CA2487899A1 (en) * 2002-06-07 2003-12-18 Yamanouchi Pharmaceutical Co., Ltd. Overactive bladder treating drug
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
JP2006514982A (ja) * 2003-03-21 2006-05-18 マクニール−ピーピーシー・インコーポレイテッド 非ステロイド抗炎症薬投薬計画
EP1492519B1 (en) * 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders using antimuscarinics and alpha-2-delta subunit calcium channel modulators
EP1627876A1 (en) * 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
EP2248524A3 (en) * 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
CA2612508A1 (en) * 2005-06-17 2006-12-28 Dynamis Therapeutics, Inc. Treatment of inflammatory conditions
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
PT1933833E (pt) * 2005-09-02 2011-07-08 Theravida Inc Terapia para o tratamento da bexiga superactiva
US20120064159A1 (en) * 2009-05-28 2012-03-15 Aptapharma, Inc. Multilayer Oral Tablets Containing a Non-Steroidal Anti-Inflammatory Drug and/or Acetaminophen
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction

Also Published As

Publication number Publication date
JP2018138602A (ja) 2018-09-06
ZA201406146B (en) 2016-08-31
NZ630471A (en) 2016-04-29
BR112014020113A2 (enrdf_load_stackoverflow) 2017-06-20
RU2014142025A (ru) 2016-05-10
CA2866755A1 (en) 2013-09-26
CN107157991A (zh) 2017-09-15
KR20140134333A (ko) 2014-11-21
AU2013235507B2 (en) 2017-03-23
AU2017203139B2 (en) 2018-07-19
AU2013235518A1 (en) 2014-09-25
HK1243921A1 (zh) 2018-07-27
CA2866853A1 (en) 2013-07-26
NZ628079A (en) 2016-05-27
ZA201405862B (en) 2016-08-31
NZ718163A (en) 2017-09-29
RU2669565C2 (ru) 2018-10-12
AU2013235518B2 (en) 2017-03-02
MX2019008817A (es) 2019-09-26
RU2016133305A3 (enrdf_load_stackoverflow) 2018-12-10
RU2016133305A (ru) 2018-12-10
EP2827851A1 (en) 2015-01-28
CN104321056A (zh) 2015-01-28
NZ712594A (en) 2016-09-30
AU2017203246A1 (en) 2017-06-08
MY174090A (en) 2020-03-09
BR112014020271A2 (enrdf_load_stackoverflow) 2017-06-20
JP2018024693A (ja) 2018-02-15
SG11201500409SA (en) 2015-03-30
AU2013235518A2 (en) 2014-10-09
HK1251469A1 (zh) 2019-02-01
EP2827851A4 (en) 2015-10-14
KR20170015537A (ko) 2017-02-08
MX2014011128A (es) 2015-08-10
AU2013235507A1 (en) 2014-08-21
MY175764A (en) 2020-07-08
BR112014020113A8 (pt) 2017-07-11
JP2015510928A (ja) 2015-04-13
SG11201500408VA (en) 2015-03-30
KR20140134284A (ko) 2014-11-21
RU2599017C2 (ru) 2016-10-10
JP2016172752A (ja) 2016-09-29
NZ714662A (en) 2016-08-26
EP2827852A4 (en) 2016-03-02
EP2827852A1 (en) 2015-01-28
AU2017203139A1 (en) 2017-06-01
CN104302284A (zh) 2015-01-21
NZ714288A (en) 2016-12-23
CN107789626A (zh) 2018-03-13
AU2017203246B2 (en) 2018-10-18
KR20190003840A (ko) 2019-01-09
BR112014020271A8 (pt) 2017-07-11
JP2015510936A (ja) 2015-04-13
WO2013142274A1 (en) 2013-09-26
RU2014142066A (ru) 2016-05-10
WO2013142197A1 (en) 2013-09-26
MX2014011129A (es) 2015-08-10

Similar Documents

Publication Publication Date Title
US20130196012A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
HK1243921A1 (zh) 用於缓解尿频的延长释放制剂及其使用方法
JP2018087217A (ja) 排尿頻度を減少させるための延長放出製剤およびその使用の方法
AU2018208765A1 (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
HK1248549A1 (zh) 用於緩解尿頻的延長釋放製劑及其使用方法
HK1256098A1 (zh) 延缓、延迟和立即释放型制剂及其制造方法和用途
CN108391420A (zh) 用于减少排尿频率的组合物及其制备方法和应用
EP2612663A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
TWI587879B (zh) 用於減少排尿頻率的延長釋放製劑及其使用方法
HK1259770A1 (en) Composition for reducing the frequency of urination, method of making and use thereof
HK1257452A1 (zh) 缓解尿频的组合物，其制造方法和应用
HK1259497A1 (en) Composition for reducing the frequency of urination, method of making and use thereof
KR20180066113A (ko) 배뇨 빈도 감소용 조성물, 제조 방법 및 용도
HK1187241A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof